Pascal Deschatelets is Chief Scientific Officer of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 1.14 Million shares of APLS, which is worth approximately $37.3 Million. The most recent transaction as insider was on May 20, 2024, when has been sold 24,500 shares (Common Stock) at a price of $3.76 per share, resulting in proceeds of $92,120. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.14M
0% 3M change
2.12% 12M change
Total Value Held $37.3 Million

Pascal Deschatelets Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 20 2024
BUY
Exercise of conversion of derivative security
$92,120 $3.76 p/Share
24,500 Added 2.1%
1,140,483 Common Stock
May 08 2024
SELL
Open market or private sale
$3,393,790 $43.01 p/Share
78,907 Reduced 6.6%
1,115,983 Common Stock
May 08 2024
BUY
Exercise of conversion of derivative security
$340,089 $4.31 p/Share
78,907 Added 6.19%
1,194,890 Common Stock
Apr 08 2024
SELL
Open market or private sale
$3,767,713 $54.52 p/Share
69,107 Reduced 5.83%
1,115,983 Common Stock
Apr 08 2024
BUY
Exercise of conversion of derivative security
$259,842 $3.76 p/Share
69,107 Added 5.51%
1,185,090 Common Stock
Mar 08 2024
SELL
Open market or private sale
$4,328,862 $62.64 p/Share
69,107 Reduced 5.83%
1,115,983 Common Stock
Mar 08 2024
BUY
Exercise of conversion of derivative security
$253,622 $3.67 p/Share
69,107 Added 5.51%
1,185,090 Common Stock
Feb 12 2024
SELL
Open market or private sale
$77,799 $67.77 p/Share
1,148 Reduced 0.1%
1,115,983 Common Stock
Jan 29 2024
SELL
Open market or private sale
$56,058 $64.14 p/Share
874 Reduced 0.08%
1,117,131 Common Stock
Jan 22 2024
SELL
Open market or private sale
$254,345 $65.0 p/Share
3,913 Reduced 0.35%
1,118,005 Common Stock
Jan 16 2024
SELL
Open market or private sale
$109,033 $66.81 p/Share
1,632 Reduced 0.15%
1,121,918 Common Stock
Jan 16 2024
BUY
Grant, award, or other acquisition
-
6,743 Added 0.6%
1,123,550 Common Stock
Nov 14 2023
BUY
Exercise of conversion of derivative security
$169,200 $3.76 p/Share
45,000 Added 3.87%
1,116,807 Common Stock
Nov 08 2023
SELL
Open market or private sale
$567,240 $47.27 p/Share
12,000 Reduced 1.11%
1,071,807 Common Stock
Nov 08 2023
BUY
Exercise of conversion of derivative security
$46,708 $2.67 p/Share
17,494 Added 1.59%
1,083,807 Common Stock
Oct 09 2023
SELL
Open market or private sale
$484,560 $40.38 p/Share
12,000 Reduced 1.11%
1,066,313 Common Stock
Oct 09 2023
BUY
Exercise of conversion of derivative security
$49,395 $2.67 p/Share
18,500 Added 1.69%
1,078,313 Common Stock
Sep 08 2023
SELL
Open market or private sale
$514,439 $42.87 p/Share
12,000 Reduced 1.12%
1,059,813 Common Stock
Sep 08 2023
BUY
Exercise of conversion of derivative security
$49,395 $2.67 p/Share
18,500 Added 1.7%
1,071,813 Common Stock
Aug 08 2023
SELL
Open market or private sale
$283,920 $23.66 p/Share
12,000 Reduced 1.13%
1,053,313 Common Stock
Aug 08 2023
BUY
Exercise of conversion of derivative security
$49,395 $2.67 p/Share
18,500 Added 1.71%
1,065,313 Common Stock
Jul 10 2023
SELL
Open market or private sale
$1,014,600 $84.55 p/Share
12,000 Reduced 1.13%
1,046,813 Common Stock
Jul 10 2023
BUY
Exercise of conversion of derivative security
$49,395 $2.67 p/Share
18,500 Added 1.72%
1,058,813 Common Stock
Jun 08 2023
SELL
Open market or private sale
$1,096,200 $91.35 p/Share
12,000 Reduced 1.14%
1,040,313 Common Stock
Jun 08 2023
BUY
Exercise of conversion of derivative security
$49,395 $2.67 p/Share
18,500 Added 1.73%
1,052,313 Common Stock
PD

Pascal Deschatelets

Chief Scientific Officer
Waltham, MA

Track Institutional and Insider Activities on APLS

Follow Apellis Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS